Elsevier Business Intelligence and the BayHelix Group will conduct the 3rd PharmAsia Summit , from September 24 - 26, 2012, in Shanghai.
Most biopharma executives seem to agree that the current model for innovation is broken. From declining R&D productivity, to demands from payers to show real-world value, to the much publicised patent cliff, the industry faces unprecedented challenges that require fundamental changes across the entire value chain. The PharmAsia Summit will discuss these strategic challenges and potential solutions for renewed growth.
The rise of emerging markets is seen to have provided multinationals with significant new growth opportunities and cash flow – but also the challenge to achieve better health outcomes in regions struggling with affordability barriers and huge unmet medical needs. Given the scope of challenges, there is a sense of urgency and government focus in emerging markets, creating a ripe environment for companies to test new R&D and business models in collaboration with industry peers, governments, payers, academia, contract research organisations, healthcare professionals and other key stakeholders.
At the PharmAsia Summit-Shanghai, Elsevier and BayHelix will feature data and case studies from China, India and other emerging markets focusing on two key imperatives of innovation - Getting Better Products To Market Faster; and Creating Value For Patients And Payers. Summit attendees can expect to get a firsthand look at innovation in China by opting to tour a local science and technology park as part of a special conference delegation.
To kick off the Summit, Elsevier, BayHelix and the Monitor Group will release an exclusive report exploring how China could disrupt the innovation paradigm, based on an industry survey and discussions with key corporate leaders and policy makers.
